Scotiabank initiated coverage of Vertex Pharmaceuticals (VRTX) with an Outperform rating and $495 price target Published first on TheFly – the ...
With immunology and inflammation blockbusters like AbbVie’s Skyrizi and Rinvoq reeling in nearly $7 billion combined in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback